<https://asweetlife.org/still-hungry-the-mixed-meal-tolerance-test-leaves-something-to-be-desired#blogposting>
<http://schema.org/description>
"As I have previously discussed, I am participating in the Protégé Encore study, which is an anti-CD3 monoclonal antibody clinical trial that is trying to prove the effectiveness of an investigational drug called teplizumab.  We all know that type 1 diabetes is an autoimmune condition where autoantibodies are attacking and killing off the body’s pancreatic beta cells.  Among other things, beta cells produce insulin, so damaged beta cells lead to decreased levels of insulin production… which leads to a diabetes diagnosis.  I enrolled in the Protégé Encore study and got a nice, long infusion of this drug, teplizumab, so (hopefully!) my body is now doing things a little differently.  As my study doctor explained to me, teplizumab acts as a body builder standing outside of a restaurant where autoantibodies hang out.  As the autoantibodies walk out of this restaurant, the body builder steps out of the dark alley and knocks out the autoantibodies.  They are not dead; they eventually wake&hellip;"
<https://asweetlife.org/still-hungry-the-mixed-meal-tolerance-test-leaves-something-to-be-desired/?wpfpaction=add&postid=9959>